Učitavanje...
Checkpoint inhibitor failure in hypermutated and mismatch repair-mutated recurrent high-grade gliomas
BACKGROUND: Recurrent high-grade gliomas in adults remain a deadly cancer with median survival of less than 1 year. In the absence of effective agents, immunotherapy with checkpoint inhibitors has been adopted as a potentially beneficial next step for recurrences with hypermutated or mismatch repair...
Spremljeno u:
| Izdano u: | Neurooncol Pract |
|---|---|
| Glavni autori: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Oxford University Press
2019
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6899050/ https://ncbi.nlm.nih.gov/pubmed/31832212 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/nop/npz016 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|